biomarker_id,biomarker_name,molecular_class,biomaterial,analytical_method,sensitivity_percent,specificity_percent,disease_specificity,age_group_performance,data_source,clinical_application,sensitivity_range,specificity_range,auc_range,condition
B001,GDF-15,Protein (cytokine),Serum/Plasma,ELISA,83.0,92.0,"General MD, best for mtDNA translation defects",Adult > Pediatric,systematic_review_biomarkers,,,,,
B002,FGF-21,Protein (growth factor),Serum/Plasma,ELISA,71.0,88.0,"General MD, muscle involvement",Adult = Pediatric,systematic_review_biomarkers,,,,,
B003,CSF Neurofilament Light,Protein (structural),CSF,Simoa/ELISA,90.0,90.0,"Neurological MD (ME, Leigh, MELAS)",Pediatric (main studies),systematic_review_biomarkers,,,,,
B004,Serum Neurofilament Light,Protein (structural),Serum/Plasma,Simoa,25.0,94.0,CNS involvement in MD,Adult = Pediatric,systematic_review_biomarkers,,,,,
B005,Cell-free circulating mtDNA,Nucleic acid (mtDNA),Plasma,qPCR,44.0,94.0,"MELAS, mtDNA disorders",Adult (main studies),systematic_review_biomarkers,,,,,
B006,CSF Lactate,Small molecule,CSF,Spectrophotometry,88.0,88.0,Neurological MD,Pediatric (main studies),systematic_review_biomarkers,,,,,
B007,Plasma Lactate,Small molecule,Plasma,Spectrophotometry,34.0,83.0,General screening,Adult = Pediatric,systematic_review_biomarkers,,,,,
B008,CSF Alanine,Amino acid,CSF,Ion exchange chromatography,75.0,76.0,General MD,Adult = Pediatric,systematic_review_biomarkers,,,,,
B009,Plasma Alanine,Amino acid,Plasma,Ion exchange chromatography,50.0,76.0,General MD,Adult = Pediatric,systematic_review_biomarkers,,,,,
B010,Lactate/Pyruvate Ratio,Metabolite ratio,Plasma/CSF,Spectrophotometry,31.0,100.0,ETC defects,Adult = Pediatric,systematic_review_biomarkers,,,,,
B011,Creatine (plasma),Small molecule,Plasma,Spectrophotometry/LC-MS,27.0,76.0,Severe MD cases,Adult (main studies),systematic_review_biomarkers,,,,,
B012,Malondialdehyde,Lipid (aldehyde),Plasma,Spectrophotometry/HPLC,,,Oxidative stress in MD,Adult (main studies),systematic_review_biomarkers,,,,,
B013,Glutathione (reduced),Tripeptide,Plasma/Erythrocytes,Spectrophotometry,,,Oxidative stress in MD,Adult (main studies),systematic_review_biomarkers,,,,,
B014,3-Methylglutaconic acid (urine),Organic acid,Urine,GC-MS,11.0,,"Specific syndromes (Barth, ATPase defects)",Pediatric (main studies),systematic_review_biomarkers,,,,,
B015,Acylcarnitines,Lipid derivatives,Plasma,Tandem MS,,,Fatty acid oxidation defects,Pediatric screening,systematic_review_biomarkers,,,,,
B016,Thiosulfate (EE),Sulfur metabolite,Plasma/Urine,HPLC/GC-MS,100.0,95.0,Ethylmalonic encephalopathy,Pediatric (infantile EE),systematic_review_biomarkers,,,,,
B017,Cardiolipin ratios (Barth),Phospholipid,Platelets/Muscle,LC-MS/MS,100.0,100.0,Barth syndrome,Pediatric/Adult,systematic_review_biomarkers,,,,,
B018,CoQ10 (plasma),Quinone,Plasma,HPLC-UV/ED,,,CoQ10 deficiency,Adult > Pediatric,systematic_review_biomarkers,,,,,
B019,Ubiquinol/ubiquinone ratio,Redox ratio,Plasma,HPLC,,,"CoQ10 deficiency, oxidative stress",Adult > Pediatric,systematic_review_biomarkers,,,,,
B020,GDF-15,Protein (cytokine),Serum/Plasma,ELISA,83.0,92.0,,,mitochondrial_biomarkers_performance,Diagnosis/Screening,,,,
B021,FGF-21,Protein (growth factor),Serum/Plasma,ELISA,71.0,88.0,,,mitochondrial_biomarkers_performance,Diagnosis/Screening,,,,
B022,Creatine,Small molecule (guanidino compound),Plasma/Serum,Spectrophotometry/LC-MS,27.0,76.0,,,mitochondrial_biomarkers_performance,Diagnosis (severe cases),,,,
B023,Cell-free circulating mtDNA,Nucleic acid (mitochondrial DNA),Plasma,qPCR,44.0,94.0,,,mitochondrial_biomarkers_performance,MELAS monitoring,,,,
B024,CSF Lactate,Small molecule (organic acid),CSF,Spectrophotometry,90.0,88.0,,,mitochondrial_biomarkers_performance,Neurological diagnosis,,,,
B025,Plasma Lactate,Small molecule (organic acid),Plasma,Spectrophotometry,34.0,83.0,,,mitochondrial_biomarkers_performance,General screening,,,,
B026,CSF Alanine,Amino acid,CSF,Ion exchange chromatography,75.0,76.0,,,mitochondrial_biomarkers_performance,Diagnosis/Monitoring,,,,
B027,Plasma Alanine,Amino acid,Plasma,Ion exchange chromatography,50.0,76.0,,,mitochondrial_biomarkers_performance,Diagnosis/Monitoring,,,,
B028,Lactate/Pyruvate Ratio,Ratio (organic acids),Plasma/CSF,Spectrophotometry,31.0,100.0,,,mitochondrial_biomarkers_performance,Pyruvate metabolism,,,,
B029,CSF Neurofilament Light,Protein (structural),CSF,Simoa/ELISA,90.0,,,,mitochondrial_biomarkers_performance,Prognosis/Monitoring,,,,
B030,Serum Neurofilament Light,Protein (structural),Serum/Plasma,Simoa,25.0,94.0,,,mitochondrial_biomarkers_performance,CNS involvement,,,,
B031,Malondialdehyde,Lipid (aldehyde),Plasma,Spectrophotometry/HPLC,,,,,mitochondrial_biomarkers_performance,Oxidative stress,,,,
B032,Glutathione (reduced),Tripeptide (antioxidant),Plasma/Erythrocytes,Spectrophotometry,,,,,mitochondrial_biomarkers_performance,Oxidative stress,,,,
B033,3-Methylglutaconic acid (urine),Small molecule (organic acid),Urine,GC-MS,11.0,,,,mitochondrial_biomarkers_performance,Specific syndromes,,,,
B034,Acylcarnitines,Acyl-CoA derivatives,Plasma,Tandem MS (MS/MS),,,,,mitochondrial_biomarkers_performance,Fatty acid disorders,,,,
B035,Serum Neurofilament light chain (NfL),protein,Blood samples (serum),ELISA; Simoa; Chemiluminescence,,,,,original_analysis,"Potential biomarker for neurological dysfunction in MELAS patients, and for monitoring disease progression.",Not reported,Not reported,Not reported,MELAS (Mitochondrial Encephalomyopathy Lactic Acidosis Stroke-like episodes)
B036,FGF21,protein,"Plasma, serum",ELISA; PCR; dd-PCR; Colorimetric; AlphaLisa,,,,,original_analysis,"Diagnosis of primary mitochondrial disease, monitoring disease course, evaluating therapy efficacy.",44%; 64%; 97%,Not reported,0.61; 0.73; 0.62,Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
B037,GDF-15,protein,"Plasma, serum",ELISA; PCR; dd-PCR; Colorimetric; AlphaLisa,,,,,original_analysis,"Diagnosis of primary mitochondrial disease, monitoring disease course, evaluating therapy efficacy.",44%; 64%; 97%,Not reported,0.61; 0.73; 0.62,Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
B038,Creatine,metabolite,"Plasma, serum",ELISA; PCR; dd-PCR; Colorimetric; AlphaLisa,,,,,original_analysis,"Diagnosis of primary mitochondrial disease, monitoring disease course, evaluating therapy efficacy.",44%; 64%; 97%,Not reported,0.61; 0.73; 0.62,Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
B039,ccf-mtDNA,dna,"Plasma, serum",ELISA; PCR; dd-PCR; Colorimetric; AlphaLisa,,,,,original_analysis,"Diagnosis of primary mitochondrial disease, monitoring disease course, evaluating therapy efficacy.",44%; 64%; 97%,Not reported,0.61; 0.73; 0.62,Myoclonic Epilepsy with Ragged Red Fibers (MERRF)
B040,Creatine kinase,protein,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B041,GDF-15,protein,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B042,FGF-21,protein,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B043,Gelsolin,protein,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B044,Neurofilament light-chain,protein,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B045,Lactate,metabolite,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B046,Pyruvate,metabolite,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B047,Lactate:Pyruvate ratio,metabolite,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B048,Creatine,metabolite,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B049,Malondialdehyde,metabolite,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B050,Circulating cell-free mtDNA (nucleic acid),dna,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B051,Amino acids (metabolite - Alanine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B052,Arginine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B053,Citrulline,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B054,Valine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B055,Leucine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B056,Isoleucine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B057,ADMA,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B058,Cysteine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B059,Histidine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B060,1-Methyl-histidine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B061,Lysine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B062,Asparagine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B063,Glutamate,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B064,Glutamine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B065,Glycine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B066,Methionine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B067,Phosphoserine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B068,Serine,other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B069,Threonine),other,"Blood (plasma, serum, arterial blood, venous blood), CSF (cerebrospinal fluid), Urine.",Not specified,,,,,original_analysis,"Diagnostic, screening, monitoring, and prognostic applications for mitochondrial diseases in general. GDF-15 and FGF-21 are considered stronger diagnostic biomarkers. Further studies are needed for more specific applications in Leigh syndrome.",66-97.9%; 20-82.8%,64-97%; 57.5-97.2%,Not reported,Leigh syndrome
B070,Vitamin B12 (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B071,Holotranscobalamin (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B072,Methylmalonic acid (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B073,Total plasma homocysteine (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B074,Nicotinamide (Vitamin B3) (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B075,1-methylhistidine (Metabolite),metabolite,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B076,Taurine (Metabolite - amino acid),other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B077,Retinal Nerve Fiber Layer (RNFL) visibility scores (Imaging Biomarker),other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B078,Never fiber bundle defects (Imaging Biomarker),other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B079,Functional markers measured in blood cells (e.g.,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B080,respiratory chain complex activities,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B081,mitochondrial DNA copy number),other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B082,Biochemical markers of serum/plasma (e.g.,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B083,lactate,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B084,pyruvate,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B085,FGF-21,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B086,GDF-15),other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B087,DNA markers (e.g.,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B088,mitochondrial DNA mutations,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B089,mitochondrial DNA deletions).,other,"Serum, Plasma, Blood (including blood cells, serum, plasma).",Spectrophotometry; Chromatography,,,,,original_analysis,"Regular vitamin B12 screening in LHON mutation carriers for early treatment and potential prognosis. Potential for diagnostic use and monitoring of therapeutic interventions for taurine and nicotinamide deficiencies. MC imaging for detecting or monitoring never fiber bundle defects and quickly identifying patients with high suspicion of LHON. A panel of diverse blood biomarkers can assist in the diagnosis of primary mitochondrial disease patients, assess mitochondrial dysfunction in multifactorial diseases, and select patients for mitochondria-targeting therapies.",Not reported,94.74%,Not reported,Leber Hereditary Optic Neuropathy (LHON)
B090,Increased tau protein,protein,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B091,Low 5-methyltetrahydrofolate (5-MTHF),metabolite,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B092,Increased free sialic acid,metabolite,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B093,Increased sphingomyelin C16:0 (d18:1/C16:0),lipid,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B094,Lactate,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B095,Pyruvate,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B096,Creatine-Kinase,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B097,Amino Acids,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B098,Organic Acids,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B099,Carnitines,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B100,Oxidative Stress Parameters,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B101,FGF-21,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B102,GDF-15,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B103,microRNAs,other,"Cerebrospinal Fluid (CSF), Blood, Urine, Saliva",Chromatography,,,,,original_analysis,"Diagnosis of KSS and other mitochondrial disorders, monitoring disease progression",Not reported,Not reported,Not reported,Kearns-Sayre syndrome (KSS)
B104,and circulating cell-free mtDNA.,dna,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B105,Fibroblast Growth Factor 21 (FGF-21) and Growth Differentiation Factor 15 (GDF-15) are promising protein biomarkers. Other general mitochondrial biomarkers include lactate,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B106,pyruvate,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B107,lactate:pyruvate ratio,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B108,creatine kinase,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B109,creatine,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B110,amino acid profiles,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B111,glutathione,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B112,malondialdehyde,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B113,gelsolin,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B114,neurofilament light-chain,other,"Blood, Plasma, Serum, Cerebrospinal Fluid (CSF), Urine, Saliva, Hair follicles (for genetic testing).",ELISA,,,,,original_analysis,"Diagnosis, screening, and monitoring of mitochondrial diseases, particularly CPEO. FGF-21 and GDF-15 aid in decision-making and can precede more invasive diagnostic tests.",0.71; 0.83,0.88; 0.92,Not reported,Chronic Progressive External Ophthalmoplegia (CPEO) mitochondrial disease
B115,Elevated cerebrospinal fluid (CSF) neopterin,protein,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B116,metabolite); increased serum and CSF folate receptor blocking autoantibodies .,protein,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B117,interleukin-6 (IL-6,other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B118,protein),other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B119,interleukin-8 (IL-8,other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B120,protein),other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B121,interferon-gamma (IFN-gamma,other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B122,protein); reduced CSF 5-methyltetrahydrofolate (5MTHF,other,Cerebrospinal fluid (CSF) and serum.,ELISA; Chromatography,,,,,original_analysis,"Potential for diagnosis, monitoring disease progression, and guiding treatment (e.g., tracking changes in biomarker levels and evaluating treatment effectiveness).",Not reported,Not reported,Not reported,Alpers disease
B123,Monolysocardiolipin (MLCL) and Cardiolipin (CL),other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B124,specifically the MLCL:CL ratio. Molecular type: Lipids. Plasma amino acids (decreased plasma arginine levels),other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B125,plasma 3-methylglutaconic acid,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B126,cholesterol,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B127,cholesterol synthetic intermediates,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B128,red blood cell membrane fatty acid profiles. Molecular types: Amino acids,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B129,metabolites,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B130,lipids. Cardiolipin (CL) and Monolysocardiolipin (MLCL),other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B131,specifically the MLCL/CL ratio. Molecular type: Lipids (phospholipids).,other,"Blood spots, lymphocytes. Plasma, red blood cell membrane. Primarily localized within the inner mitochondrial membrane (tissue sections), but article discusses analysis in various model systems.",LC-MS; Chromatography,,,,,original_analysis,"Definitive diagnostic tool for Barth syndrome, especially for clinicians and geneticists working with inborn errors of metabolism. Potential biomarker for monitoring health over time. Augments and expands biochemical profiles, provides insight into possible underlying biochemical pathology. CL measurement is valuable for investigating mitochondrial dysfunction, characterizing pathophysiological mechanisms, and clinical diagnostics. MLCL/CL ratio is a sensitive diagnostic marker. CL has potential as a tissue-specific biomarker and for monitoring disease progression and efficacy during clinical trials.",Not reported,Not reported,Not reported,Barth Syndrome
B132,FGF21,protein,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B133,GDF-15,protein,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B134,Creatine,metabolite,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B135,Alanine,metabolite,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B136,Lactic Acid,metabolite,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B137,Citrulline,metabolite,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B138,ccf-mtDNA (cell-free mitochondrial DNA),dna,"Plasma, Serum, Cerebrospinal fluid (CSF), Blood",Not specified,,,,,original_analysis,Diagnostic: Identifying NARP through genetic testing and biochemical markers; Monitoring: Tracking disease progression and response to supportive treatments; Prognostic: Mutation load of mtDNA can indicate clinical severity; Screening: Early identification in childhood,Not reported,Not reported,Not reported,Neuropathy Ataxia Retinitis Pigmentosa (NARP)
B139,Carnitine ; Fumarate ; Alanine (amino acid); Arginine (amino acid); Lactate ; 3-hydroxybutyrate ; Lactate:Pyruvate ratio ; Citrulline (amino acid); 3-methylglutaconic acid ; Malic acid,metabolite,Bone marrow; Urinary epithelial cells; CSF; Buccal swabs; Urine; Serum; Blood; Peripheral blood,PCR,,,,,original_analysis,"Monitoring (mtDNA proportion changes with hematological recovery/disease progression); Diagnostic (SLSMDs detection, metabolite pattern for differential diagnosis)",34.6-88.2%; 11.5-82.4%; 76.5%; 88.2%,81.2-87.2%; 68.7-100%; 90.6%; 100%,Not reported,Pearson syndrome
B140,Glucose,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B141,galactose,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B142,mannose,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B143,sorbose,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B144,maltose (carbohydrates); 2-Hydroxybutyric acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B145,eicosapentaenoic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B146,octadecanoic acid (fatty acids); alanine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B147,threonic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B148,cholesterol,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B149,lactic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B150,gluconic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B151,threonine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B152,tryptophan,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B153,histidine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B154,proline,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B155,glutamine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B156,creatine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B157,citrulline,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B158,3-Amino-2-piperidone,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B159,ornithine,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B160,arachidonic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B161,malic acid,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B162,succinic acid (other metabolites/amino acids).,other,Serum,Chromatography,,,,,original_analysis,"Understanding the pathophysiology and underlying mechanisms of MIDD; potential for diagnostic signature.
Early diagnosis for optimal management and follow-up, differentiation from other types of diabetes, identification of at-risk family members. Genetic testing is crucial.",Not reported,Not reported,Not reported,Maternally Inherited Diabetes and Deafness (MIDD)
B163,Circulating microRNAs (miRNAs). Specifically,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B164,five plasma miRNAs (miR-192-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B165,miR-193a-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B166,miR-194-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B167,miR-215-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B168,and miR-34a-5p) and three serum miRNAs (miR-192-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B169,miR-194-5p,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B170,and miR-34a-5p) were identified.,other,Plasma and serum samples.,PCR; qPCR,,,,,original_analysis,The study suggests that the identified miRNA panel may have prognostic value for assessing clinical status and could be included in future clinical trials of investigational therapies for MNGIE.,Not reported,Not reported,Not reported,Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE)
B171,Cardiac Biomarkers: LVMI,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B172,LVEF,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B173,IVS,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B174,LVPW,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B175,FS,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B176,NT-Pro BNP,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B177,ST2,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B178,troponin,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B179,Mitochondrial FXN,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B180,follistatin,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B181,myostatin,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B182,FXN levels,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B183,FXN concentration,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B184,PBMC FXN levels .,protein,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B185,Echocardiogram (imaging). Biochemical Biomarkers: Erythrocyte protoporphyrin IX,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B186,Urinary 8OH2'dG,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B187,Antioxidants,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B188,plasma malondialdehyde,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B189,plasma DHBA,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B190,urine F2-isoprostane,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B191,serum peroxides,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B192,NADH/NAD ratio,metabolite,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B193,FXN mRNA expression (nucleic acid),other,"Not explicitly stated for each biomarker, but the study focuses on 'biofluid biomarkers' and mentions 'plasma', 'urine', 'serum', 'isolated lymphocytes', 'whole blood', 'PBMCs', 'buccal cells', and 'cerebrospinal fluid' in the context of biomarker measurement.",Not specified,,,,,original_analysis,Assessing therapeutic efficacy in Friedreich's ataxia patients; Detecting subtle disease progression.,Not reported,Not reported,Not reported,Friedreich ataxia mitochondrial disease
B194,Elevated cerebrospinal fluid (CSF) protein,other,"Cerebrospinal fluid (CSF), serum.",Not specified,,,,,original_analysis,Early diagnosis and identification of patients at high risk of developing epilepsy in POLG-related disease. Prognostic implications (poorer outcome associated with blood-brain barrier dysfunction).,Not reported,Not reported,Not reported,"POLG-related mitochondrial disease, specifically POLG-related epilepsy."
B195,raised CSF/serum ratio of albumin (Q-alb ratio). Molecular type: protein,other,"Cerebrospinal fluid (CSF), serum.",Not specified,,,,,original_analysis,Early diagnosis and identification of patients at high risk of developing epilepsy in POLG-related disease. Prognostic implications (poorer outcome associated with blood-brain barrier dysfunction).,Not reported,Not reported,Not reported,"POLG-related mitochondrial disease, specifically POLG-related epilepsy."
B196,albumin.,other,"Cerebrospinal fluid (CSF), serum.",Not specified,,,,,original_analysis,Early diagnosis and identification of patients at high risk of developing epilepsy in POLG-related disease. Prognostic implications (poorer outcome associated with blood-brain barrier dysfunction).,Not reported,Not reported,Not reported,"POLG-related mitochondrial disease, specifically POLG-related epilepsy."
B197,Circulating cell-free mtDNA (molecular type: nucleic acid),dna,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B198,Lactate (molecular type: metabolic acid),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B199,Pyruvate (molecular type: metabolic acid),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B200,Lactate:Pyruvate ratio (molecular type: metabolic ratio),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B201,Creatine Kinase (CK) (molecular type: enzyme),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B202,Creatine (molecular type: amino acid derivative),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B203,Amino Acids (molecular type: amino acids),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B204,Glutathione (molecular type: tripeptide),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B205,Malondialdehyde (molecular type: lipid peroxidation product),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B206,GDF-15 (molecular type: cytokine),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B207,FGF-21 (molecular type: hormone),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B208,Gelsolin (molecular type: protein),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B209,Neurofilament light-chain (molecular type: protein),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B210,GDF-15 (for TK2 deficiency,other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B211,molecular type: cytokine),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B212,Methylmalonic aciduria (for SUCLA2 deficiency,other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B213,molecular type: organic acid),other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B214,No specific biofluid biomarkers found for RRM2B deficiency,other,"lymphocyte samples, urine, serum, CSF, erythrocyte samples, blood/plasma",ELISA,,,,,original_analysis,"Diagnostic, Monitoring",76.5%; 22.2-34.1%; 11.5-82.4%; 15.1-100%; 34.6-88.2%,90.6%; 73.0-97.0%; 68.7-100%; 83.0-100%; 81.2-87.2%,Not reported,Mitochondrial DNA Depletion Syndrome (MDS)
B215,Coenzyme Q10 (CoQ10) levels (lipid,other,"Skeletal muscle, dermal skin fibroblasts, lymphocytes, plasma, urine",Not specified,,,,,original_analysis,"Diagnosis, monitoring treatment response, potential for screening (though plasma/white blood cell levels are not reliable for diagnosis)",Not reported,Not reported,Not reported,CoQ10 deficiency mitochondrial disease
B216,metabolite),other,"Skeletal muscle, dermal skin fibroblasts, lymphocytes, plasma, urine",Not specified,,,,,original_analysis,"Diagnosis, monitoring treatment response, potential for screening (though plasma/white blood cell levels are not reliable for diagnosis)",Not reported,Not reported,Not reported,CoQ10 deficiency mitochondrial disease
B217,FGF-21,protein,"Serum, Muscle tissue",ELISA; Immunoassay,,,,,original_analysis,"Diagnostic (general mitochondrial disorders), Monitoring therapeutic response to deoxynucleoside treatment (TK2d), Indicators of disease severity (TK2d)",0.71; 0.83,0.88; 0.92,0.90; 0.94,Thymidine Kinase 2 Deficiency (TK2d)
B218,GDF-15,protein,"Serum, Muscle tissue",ELISA; Immunoassay,,,,,original_analysis,"Diagnostic (general mitochondrial disorders), Monitoring therapeutic response to deoxynucleoside treatment (TK2d), Indicators of disease severity (TK2d)",0.71; 0.83,0.88; 0.92,0.90; 0.94,Thymidine Kinase 2 Deficiency (TK2d)
B219,Fibroblast Growth Factor 21 (FGF21) - Hormone,other,Serum,ELISA,,,,,original_analysis,"Assessment of mitochondrial damage in mt-aARS deficiency, providing insight into the level of damage.",100%,100%,0.933,Mitochondrial Aminoacyl-tRNA Synthetase Deficiency (mtARS deficiency)
B220,No specific biofluid biomarkers with molecular types were identified for Luft disease in the available literature.,other,Not specified in available literature for biofluid biomarkers of Luft disease.,Not specified,,,,,original_analysis,"Due to the extreme rarity and limited research on biofluid biomarkers for Luft disease, specific clinical applications (diagnostic, screening, monitoring, or prognostic) based on biofluid biomarkers are not established.",Not reported,Not reported,Not reported,Luft disease (nonthyroidal hypermetabolism)
B221,"Neurofilament light chain (NF-L) - protein
Fibroblast growth factor 21 (FGF-21) - protein
Growth and differentiation factor 15 (GDF-15) - protein",other,Serum,ELISA; Simoa,,,,,original_analysis,"Diagnostic tool for mitochondrial disease.
Monitoring disease activity and progression (NF-L).
Identifying muscle involvement (FGF-21 and GDF-15).
Narrowing the choice of diagnostic tests in suspected mitochondrial disease.",Not reported,Not reported,Not reported,Primary mitochondrial myopathy
